Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Allied Minds Appoints Donna See as Vice President

5 Nov 2014 07:00

RNS Number : 1558W
Allied Minds PLC
05 November 2014
 



 

For immediate release

 

Media contact:

Christine Dunn

ArcPoint Strategic Communications

617.484.1660, x101

cdunn@arcpointstrategy.com

 

Allied Minds Appoints Donna See as Vice President to Lead the Development of Technology Transfer Partnerships with U.S. Universities

· Donna See joins Allied Minds from Columbia University's Technology Ventures group, an internationally recognized leader in the field of academic tech transfer.

· With the ABLS team, Donna See will lead sourcing and identification of opportunities for Allied-Bristol Life Sciences (ABLS), a joint venture of Allied Minds and Bristol-Myers Squibb established to identify promising therapeutic opportunities.

 

· Donna See will also work closely with the company's Allied Minds Federal Innovations (AMFI) group to enhance the technology pipeline from national laboratories and federal research centers.

 

Boston (Nov. 5, 2014) -- Allied Minds (ALM: LSE), an innovative U.S. science and technology development and commercialization company,  today announced that Donna See, former Director of Licensing and Strategic Initiatives at Columbia University's technology transfer office, has joined as Vice President to lead the firm's partnerships with U.S. research universities.

Donna brings more than 14 years of experience in academic technology transfer, public-private partnerships, and early-stage technology development. She most recently served as Director of Licensing as well as Director of Strategic Initiatives for Columbia Technology Ventures, an internationally recognized leader in the field of academic tech transfer. At Columbia, Donna oversaw a diverse portfolio of over 1,000 life and physical sciences assets, spanning therapeutics, diagnostics, medtech, electronics, imaging, data sciences, semiconductors, cybersecurity and advanced materials. Under her leadership, the team reached new heights on key tech transfer metrics, closing over 105 deals and helping to launch more than 20 start-up companies in the past two years.

"Donna brings invaluable experience that will allow Allied Minds to expand our support of the relationships we already have with top universities in the U.S., and broaden our network to include a wider universe of researchers and innovators," said Chris Silva, Chief Executive Officer of Allied Minds.

In addition to her first-hand experience negotiating over 150 licenses and option agreements and advising more than 27 start-ups, Donna has served as a reviewer for the National Science Foundation Small Business Innovation Research (SBIR) program and has co-authored numerous commercialization proposals, winning more than $23 million in seed stage financing for promising projects and nascent companies.

 

She also oversaw Columbia's nationally acclaimed Fellows Program, and was founding Director of the Columbia-Coulter Translational Partnership, one of 16 university partnerships established by the Wallace. H. Coulter Foundation to propel promising university technologies into the hands of commercial partners.

"It's a privilege to be joining Allied Minds, a firm that occupies a unique position in the growing sector of early-stage technology developers," Donna said. "Allied Minds doesn't just fund companies, the team builds companies, working side-by-side with university and national lab inventors, their tech transfer champions, and experienced entrepreneurs. As funders and operators of the companies they build, Allied Minds understands the challenges and opportunities of early-stage tech commercialization. I'm very much looking forward to working with old and new friends and colleagues from the tech transfer world, with whom I hope to build value in many other ways beyond the four corners of a deal."

Prior to Columbia, Donna was Director of Business Development and Technology Transfer at New York-Presbyterian Hospital, forging strategic alliances with government and industry partners to evaluate, develop and acquire new healthcare technologies. She also spent over a decade in global and domestic public health, working with the World Bank, Centers for Disease Control, and numerous state, local and private sector organizations to improve health-care access, delivery and quality.

Donna earned her MBA from Columbia Business School and her MPH in Health Policy & Management from Columbia University's School of Public Health. She holds a BA in the Natural Sciences from Johns Hopkins University. Donna will be based out of Allied Minds' New York office.

 

About Allied Minds

Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.

Allied Minds Forward-Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risk and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Prospectus Rules, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUSOBRSSAARAA
Date   Source Headline
5th Jun 20204:40 pmRNSSecond Price Monitoring Extn
5th Jun 20204:35 pmRNSPrice Monitoring Extension
4th Jun 20207:00 amRNSAnnual Financial Report
21st May 20204:41 pmRNSSecond Price Monitoring Extn
21st May 20204:36 pmRNSPrice Monitoring Extension
11th May 20207:01 amRNSBlock listing Interim Review
11th May 20207:00 amRNSBlock listing Interim Review
27th Apr 20202:20 pmRNSDisclosure of Rights Attaching to Equity Shares
22nd Apr 20209:00 amRNSNotice of results - update
21st Apr 20207:00 amRNSFederated Wireless raises $13.7m
15th Apr 20204:40 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
3rd Apr 20204:41 pmRNSSecond Price Monitoring Extn
3rd Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20204:47 pmRNSHolding(s) in Company
25th Mar 20204:42 pmRNSSecond Price Monitoring Extn
25th Mar 20204:38 pmRNSPrice Monitoring Extension
23rd Mar 20205:04 pmRNSHolding(s) in Company
19th Mar 20205:38 pmRNSHolding(s) in Company
18th Mar 202010:00 amRNSNotice of results - update
13th Mar 20205:24 pmRNSHolding(s) in Company
11th Mar 20201:05 pmRNSFederated Wireless Extends Spectrum Controller
10th Mar 20207:00 amRNSDirectorate Changes
20th Feb 20209:40 amRNSFederated partners in UK 5G New Thinking project
18th Feb 20201:28 pmRNSFederated selects AWS as preferred cloud provider
18th Feb 20201:22 pmRNSFederated brings 4G/5G private networks to US
17th Feb 20205:20 pmRNSHolding(s) in Company
7th Feb 202010:00 amRNSNotice of Full-Year Results
3rd Feb 20207:00 amRNSTotal Voting Rights
16th Jan 20207:00 amRNSSpecial Dividend Declaration
15th Jan 20202:28 pmRNSBoeing HorizonX & BridgeComm pioneer optical mesh
2nd Jan 20202:53 pmRNSTotal Voting Rights
18th Dec 20193:31 pmRNSDirector/PDMR Shareholding
11th Dec 20193:13 pmPRNCrystal Amber withdraws requisition of Allied Minds
11th Dec 20197:00 amRNSBoard changes and restructuring initiatives
2nd Dec 20195:40 pmRNSTotal Voting Rights
28th Nov 20193:02 pmRNSDirector/PDMR Shareholding
22nd Nov 20194:26 pmRNSHolding(s) in Company
20th Nov 201911:27 amRNSHolding(s) in Company
15th Nov 201910:45 amRNSDirector/PDMR Shareholding
13th Nov 201910:11 amRNSHolding(s) in Company
11th Nov 201910:41 amRNSBlock Listing Six-Monthly Return
11th Nov 201910:15 amRNSBlock Listing Six-Monthly Return
8th Nov 20192:31 pmRNSCompletion of Disposal
7th Nov 20193:39 pmRNSHolding(s) in Company
6th Nov 201912:34 pmRNSResults of General Meeting
5th Nov 201912:02 pmRNSPrice Monitoring Extension
22nd Oct 20194:53 pmRNSHolding(s) in Company
17th Oct 20195:06 pmRNSPublication of Circular
17th Oct 20191:49 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.